3D rendering of eosinophil
|Anatomical terms of microanatomy|
Eosinophils, sometimes called eosinophiles or, less commonly, acidophils, are a variety of white blood cells and one of the immune system components responsible for combating multicellular parasites and certain infections in vertebrates. Along with mast cells and basophils, they also control mechanisms associated with allergy and asthma. They are granulocytes that develop during hematopoiesis in the bone marrow before migrating into blood, after which they are terminally differentiated and do not multiply. They form about 2 to 3% of WBC's.
These cells are eosinophilic or "acid-loving" due to their large acidophilic cytoplasmic granules, which show their affinity for acids by their affinity to coal tar dyes: Normally transparent, it is this affinity that causes them to appear brick-red after staining with eosin, a red dye, using the Romanowsky method. The staining is concentrated in small granules within the cellular cytoplasm, which contain many chemical mediators, such as eosinophil peroxidase, ribonuclease (RNase), deoxyribonucleases (DNase), lipase, plasminogen, and major basic protein. These mediators are released by a process called degranulation following activation of the eosinophil, and are toxic to both parasite and host tissues.
In normal individuals, eosinophils make up about 1–3% of white blood cells, and are about 12–17 micrometres in size with bilobed nuclei. While they are released into the bloodstream as neutrophils, eosinophils reside in tissue. They are found in the medulla and the junction between the cortex and medulla of the thymus, and, in the lower gastrointestinal tract, ovaries, uterus, spleen, and lymph nodes, but not in the lungs, skin, esophagus, or some other internal organs[vague] under normal conditions. The presence of eosinophils in these latter organs is associated with disease. For instance, patients with eosinophilic asthma have high levels of eosinophils that lead to inflammation and tissue damage, making it more difficult for patients to breathe. Eosinophils persist in the circulation for 8–12 hours, and can survive in tissue for an additional 8–12 days in the absence of stimulation. Pioneering work in the 1980s elucidated that eosinophils were unique granulocytes, having the capacity to survive for extended periods of time after their maturation as demonstrated by ex-vivo culture experiments.
TH2 and ILC2 cells both express the transcription factor GATA-3, which promotes the production of TH2 cytokines, including the interleukins (ILs). IL-5 controls the development of eosinophils in the bone marrow, as they differentiate from myeloid precursor cells. Their lineage fate is determined by transcription factors, including GATA and C/EBP. Eosinophils produce and store many secondary granule proteins prior to their exit from the bone marrow. After maturation, eosinophils circulate in blood and migrate to inflammatory sites in tissues, or to sites of helminth infection in response to chemokines like CCL11 (eotaxin-1), CCL24 (eotaxin-2), CCL5 (RANTES), 5-hydroxyicosatetraenoic acid and 5-oxo-eicosatetraenoic acid, and certain leukotrienes like leukotriene B4 (LTB4) and MCP1/4. Interleukin-13, another TH2 cytokine, primes eosinophilic exit from the bone marrow by lining vessel walls with adhesion molecules such as VCAM-1 and ICAM-1. When eosinophils are activated, they undergo cytolysis, where the breaking of the cell releases eosinophilic granules found in extracellular DNA traps. High concentrations of these DNA traps are known to cause cellular damage, as the granules they contain are responsible for the ligand-induced secretion of eosinophilic toxins which cause structural damage. There is evidence to suggest that eosinophil granule protein expression is regulated by the non-coding RNA EGOT.
Following activation, eosinophils effector functions include production of the following:
- Cationic granule proteins and their release by degranulation
- Reactive oxygen species such as hypobromite, superoxide, and peroxide (hypobromous acid, which is preferentially produced by eosinophil peroxidase)
- Lipid mediators like the eicosanoids from the leukotriene (e.g., LTC4, LTD4, LTE4) and prostaglandin (e.g., PGE2) families
- Enzymes, such as elastase
- Growth factors such as TGF beta, VEGF, and PDGF
- Cytokines such as IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-13, and TNF alpha
There are also eosinophils that play a role in fighting viral infections, which is evident from the abundance of RNases they contain within their granules, and in fibrin removal during inflammation. Eosinophils, along with basophils and mast cells, are important mediators of allergic responses and asthma pathogenesis and are associated with disease severity. They also fight helminth (worm) colonization and may be slightly elevated in the presence of certain parasites. Eosinophils are also involved in many other biological processes, including postpubertal mammary gland development, oestrus cycling, allograft rejection and neoplasia. They have also been implicated in antigen presentation to T cells.
Eosinophils are responsible for tissue damage and inflammation in many diseases, including asthma. High levels of interleukin-5 has been observed to up regulate the expression of adhesion molecules, which then facilitate the adhesion of eosinophils to endothelial cells, thereby causing inflammation and tissue damage.
Following activation by an immune stimulus, eosinophils degranulate to release an array of cytotoxic granule cationic proteins that are capable of inducing tissue damage and dysfunction. These include:
- major basic protein (MBP)
- eosinophil cationic protein (ECP)
- eosinophil peroxidase (EPX)
- eosinophil-derived neurotoxin (EDN)
Major basic protein, eosinophil peroxidase, and eosinophil cationic protein are toxic to many tissues. Eosinophil cationic protein and eosinophil-derived neurotoxin are ribonucleases with antiviral activity. Major basic protein induces mast cell and basophil degranulation, and is implicated in peripheral nerve remodelling. Eosinophil cationic protein creates toxic pores in the membranes of target cells, allowing potential entry of other cytotoxic molecules to the cell, can inhibit proliferation of T cells, suppress antibody production by B cells, induce degranulation by mast cells, and stimulate fibroblast cells to secrete mucus and glycosaminoglycan. Eosinophil peroxidase forms reactive oxygen species and reactive nitrogen intermediates that promote oxidative stress in the target, causing cell death by apoptosis and necrosis.
An increase in eosinophils, i.e., the presence of more than 500 eosinophils/microlitre of blood is called an eosinophilia, and is typically seen in people with a parasitic infestation of the intestines; autoimmune and collagen vascular disease (such as rheumatoid arthritis) and Systemic lupus erythematosus; malignant diseases such as eosinophilic leukemia, clonal hypereosinophilia, and Hodgkin's disease; lymphocyte-variant hypereosinophilia; extensive skin diseases (such as exfoliative dermatitis); Addison's disease and other causes of low corticosteroid production (corticosteroids suppress blood eosinophil levels); reflux esophagitis (in which eosinophils will be found in the squamous epithelium of the esophagus) and eosinophilic esophagitis; and with the use of certain drugs such as penicillin. But, perhaps the most common cause for eosinophilia is an allergic condition such as asthma. In 1989, contaminated L-tryptophan supplements caused a deadly form of eosinophilia known as eosinophilia-myalgia syndrome, which was reminiscent of the toxic oil syndrome in Spain in 1981.
Eosinophils play an important role in asthma as the number of accumulated eosinophils corresponds to the severity of asthmatic reaction. Eosinophilia in mice models are shown to be associated with high interleukin-5 levels. Furthermore, mucosal bronchial biopsies conducted on patients with diseases such as asthma have been found to have higher levels of interleukin-5 leading to higher levels of eosinophils. The infiltration of eosinophils at these high concentrations causes an inflammatory reaction. This ultimately leads to airway remodelling and difficulty of breathing.
Eosinophils can also cause tissue damage in the lungs of asthmatic patients. High concentrations of eosinophil major basic protein and eosinophil-derived neurotoxin that approach cytotoxic levels are observed at degranulation sites in the lungs as well as in the asthmatic sputum.
Treatments used to combat autoimmune diseases and conditions caused by eosinophils include:
- corticosteroids – promote apoptosis. Numbers of eosinophils in blood are rapidly reduced
- monoclonal antibody therapy – e.g., mepolizumab or reslizumab against IL-5, prevents eosinophilopoiesis
- antagonists of leukotriene synthesis or receptors
- imatinib (STI571) – inhibits PDGF-BB in hypereosinophilic leukemia
Monoclonal antibodies such as dupilumab and lebrikizumab target IL-13 and its receptor, which reduces eosinophilic inflammation in patients with asthma due to lowering the number of adhesion molecules present for eosinophils to bind to, thereby decreasing inflammation. Mepolizumab and benralizumab are other treatment options that target the alpha subunit of the IL-5 receptor, thereby inhibiting its function and reducing the number of developing eosinophils as well as the number of eosinophils leading to inflammation through antibody-dependent cell-mediated cytotoxicity and eosinophilic apoptosis.
Within the fat (adipose) tissue of CCR2 deficient mice, there is an increased number of eosinophils, greater alternative macrophage activation, and a propensity towards type 2 cytokine expression. Furthermore, this effect was exaggerated when the mice became obese from a high fat diet. Mouse models of eosinophilia from mice infected with T. canis showed an increase in IL-5 mRNA in mice spleen. Mouse models of asthma from OVA show a higher TH2 response. When mice are administered IL-12 to induce the TH1 response, the TH2 response becomes suppressed, showing that mice without TH2 cytokines are significantly less likely to express asthma symptoms.
- Eosinopenia, decrease in eosinophil blood count
- Eosinophilia, increase (>500 cells per microliter) in eosinophil blood count
- Hypereosinophilia, extreme increase (>1,500 cells per microliter) in eosinophil blood count
- Clonal hypereosinophilia, presence of a premalignant or malignant clone of eosinophils in bone marrow and blood
- Chronic eosinophilic leukemia
- "eosinophil - Definition of eosinophil in English by Oxford Dictionaries". Oxford Dictionaries - English. Retrieved 27 March 2018.
- "What is an Eosinophil? | Definition & Function | CCED". www.cincinnatichildrens.org. Retrieved 14 June 2018.
- Uhm TG, Kim BS, Chung IY (March 2012). "Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma". Allergy, Asthma & Immunology Research. 4 (2): 68–79. doi:10.4168/aair.2012.4.2.68. PMC 3283796. PMID 22379601.
- Rosenberg HF, Phipps S, Foster PS (June 2007). "Eosinophil trafficking in allergy and asthma". The Journal of Allergy and Clinical Immunology. 119 (6): 1303–10, quiz 1311–2. doi:10.1016/j.jaci.2007.03.048. hdl:1885/30451. PMID 17481712.
- Young B, Lowe jo, Stevens A, Heath JW (2006). Wheater's Functional Histology (5th ed.). Elsevier Limited. ISBN 978-0-443-06850-8.
- Lambrecht BN, Hammad H (January 2015). "The immunology of asthma". Nature Immunology. 16 (1): 45–56. doi:10.1038/ni.3049. PMID 25521684. S2CID 5451867.
- Sanderson, Colin (1992). "Interleukin-5, Eosinophils, and Disease". Blood. 79 (12): 3101–3109. doi:10.1182/blood.V79.12.3101.bloodjournal79123101. PMID 1596561.
- Young B, Lowe JS, Stevens A, Heath JW (2006). Wheater's Functional Histology (5th ed.). Elsevier Limited. ISBN 978-0-443-06850-8.
- Park YM, Bochner BS (April 2010). "Eosinophil survival and apoptosis in health and disease". Allergy, Asthma & Immunology Research. 2 (2): 87–101. doi:10.4168/aair.2010.2.2.87. PMC 2846745. PMID 20358022.
- Metcalf D, Begley CG, Nicola NA, Johnson GR (March 1987). "Quantitative responsiveness of murine hemopoietic populations in vitro and in vivo to recombinant multi-CSF (IL-3)". Experimental Hematology. 15 (3): 288–95. PMID 3493174.
- Metcalf D, Burgess AW, Johnson GR, Nicola NA, Nice EC, DeLamarter J, Thatcher DR, Mermod JJ (September 1986). "In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: comparison with purified native GM-CSF". Journal of Cellular Physiology. 128 (3): 421–31. doi:10.1002/jcp.1041280311. PMID 3528176. S2CID 515338.
- Yamaguchi Y, Suda T, Suda J, Eguchi M, Miura Y, Harada N, Tominaga A, Takatsu K (January 1988). "Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors". The Journal of Experimental Medicine. 167 (1): 43–56. doi:10.1084/jem.167.1.43. PMC 2188821. PMID 3257253.
- Wagner LA, Christensen CJ, Dunn DM, Spangrude GJ, Georgelas A, Kelley L, Esplin MS, Weiss RB, Gleich GJ (June 2007). "EGO, a novel, noncoding RNA gene, regulates eosinophil granule protein transcript expression". Blood. 109 (12): 5191–8. doi:10.1182/blood-2006-06-027987. PMC 1890841. PMID 17351112.
- Trulson A, Byström J, Engström A, Larsson R, Venge P (February 2007). "The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications". Clinical and Experimental Allergy. 37 (2): 208–18. doi:10.1111/j.1365-2222.2007.02644.x. PMID 17250693. S2CID 45301814.
- Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, Kay AB, Rothenberg ME (May 2008). "Eosinophils: biological properties and role in health and disease". Clinical and Experimental Allergy. 38 (5): 709–50. doi:10.1111/j.1365-2222.2008.02958.x. PMID 18384431. S2CID 25254034.
- Lacy P (September 2005). "The role of Rho GTPases and SNAREs in mediator release from granulocytes". Pharmacology & Therapeutics. 107 (3): 358–76. doi:10.1016/j.pharmthera.2005.03.008. PMID 15951020.
- Saito K, Nagata M, Kikuchi I, Sakamoto Y (December 2004). "Leukotriene D4 and eosinophil transendothelial migration, superoxide generation, and degranulation via beta2 integrin". Annals of Allergy, Asthma & Immunology. 93 (6): 594–600. doi:10.1016/S1081-1206(10)61269-0. PMID 15609771.
- Bandeira-Melo C, Bozza PT, Weller PF (March 2002). "The cellular biology of eosinophil eicosanoid formation and function". The Journal of Allergy and Clinical Immunology. 109 (3): 393–400. doi:10.1067/mai.2002.121529. PMID 11897981.
- Kato Y, Fujisawa T, Nishimori H, Katsumata H, Atsuta J, Iguchi K, Kamiya H (2005). "Leukotriene D4 induces production of transforming growth factor-beta1 by eosinophils". International Archives of Allergy and Immunology. 137. 137 Suppl 1 (1): 17–20. doi:10.1159/000085427. PMID 15947480. S2CID 23556551.
- Horiuchi T, Weller PF (July 1997). "Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5". American Journal of Respiratory Cell and Molecular Biology. 17 (1): 70–7. doi:10.1165/ajrcmb.17.1.2796. PMID 9224211.
- Rothenberg ME, Hogan SP (2006). "The eosinophil". Annual Review of Immunology. 24 (1): 147–74. doi:10.1146/annurev.immunol.24.021605.090720. PMID 16551246.
- Shi HZ (September 2004). "Eosinophils function as antigen-presenting cells". Journal of Leukocyte Biology. 76 (3): 520–7. doi:10.1189/jlb.0404228. PMID 15218055. S2CID 25152503.
- Gleich GJ, Adolphson CR (1986). "The eosinophilic leukocyte: structure and function". Advances in Immunology Volume 39. Advances in Immunology. 39. pp. 177–253. doi:10.1016/S0065-2776(08)60351-X. ISBN 9780120224395. PMID 3538819.
- Slifman NR, Loegering DA, McKean DJ, Gleich GJ (November 1986). "Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein". Journal of Immunology. 137 (9): 2913–7. PMID 3760576.
- Zheutlin LM, Ackerman SJ, Gleich GJ, Thomas LL (October 1984). "Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins". Journal of Immunology. 133 (4): 2180–5. PMID 6206154.
- Morgan RK, Costello RW, Durcan N, Kingham PJ, Gleich GJ, McLean WG, Walsh MT (August 2005). "Diverse effects of eosinophil cationic granule proteins on IMR-32 nerve cell signaling and survival". American Journal of Respiratory Cell and Molecular Biology. 33 (2): 169–77. CiteSeerX 10.1.1.335.4162. doi:10.1165/rcmb.2005-0056OC. PMID 15860794.
- Young JD, Peterson CG, Venge P, Cohn ZA (1986). "Mechanism of membrane damage mediated by human eosinophil cationic protein". Nature. 321 (6070): 613–6. Bibcode:1986Natur.321..613Y. doi:10.1038/321613a0. PMID 2423882. S2CID 4322838.
- Venge P, Byström J, Carlson M, Hâkansson L, Karawacjzyk M, Peterson C, Sevéus L, Trulson A (September 1999). "Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease". Clinical and Experimental Allergy. 29 (9): 1172–86. doi:10.1046/j.1365-2222.1999.00542.x. PMID 10469025. S2CID 11541968.
- Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G (June 2013). "Dupilumab in persistent asthma with elevated eosinophil levels". The New England Journal of Medicine. 368 (26): 2455–66. doi:10.1056/nejmoa1304048. PMID 23688323.
- Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG (September 2011). "Lebrikizumab treatment in adults with asthma". The New England Journal of Medicine. 365 (12): 1088–98. doi:10.1056/nejmoa1106469. PMID 21812663.
- Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA (November 2013). "Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia". The Journal of Allergy and Clinical Immunology. 132 (5): 1086–1096.e5. doi:10.1016/j.jaci.2013.05.020. PMC 4172321. PMID 23866823.
- Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P (September 2014). "Mepolizumab treatment in patients with severe eosinophilic asthma". The New England Journal of Medicine. 371 (13): 1198–207. doi:10.1056/nejmoa1403290. PMID 25199059.
- Bolus WR, Gutierrez DA, Kennedy AJ, Anderson-Baucum EK, Hasty AH (October 2015). "CCR2 deficiency leads to increased eosinophils, alternative macrophage activation, and type 2 cytokine expression in adipose tissue". Journal of Leukocyte Biology. 98 (4): 467–77. doi:10.1189/jlb.3HI0115-018R. PMC 4763864. PMID 25934927. Archived from the original on 9 May 2017. Retrieved 8 September 2016.
- Eosinophil[dead link] - BioWeb at University of Wisconsin System
- Histology at ucsf.edu
- "What is an eosinophil?" at the Cincinnati Center for Eosinophilic Disorders